+44 (0) 1223 737941 enquiries@cn-bio.com
  • Events
  • News
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
  • Events
  • News
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
CN Bio
  • Home
  • CN Bio
    • The Company
    • Management Team
    • Careers
  • Organ-On-Chip
    • About Organ-On-Chip
    • Liver-On-Chip
    • Barrier Models
    • 3D Cell Culture
    • Toxicology
    • Drug Metabolism
    • Disease Modelling
  • Products & Services
    • PhysioMimix™ OOC
      • Product Information
      • Consumables
      • T12
      • LC12
    • Human Cell Referral
    • NASH Fee-For-Service
    • Drug Metabolism and Safety Toxicity Testing Services
  • Resources
    • Scientific Publications
    • Brochures
    • Videos
  • Contact
Select Page

CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research

by CN Bio. | Mar 1, 2021 | Press releases

Funding will advance 3D lung cell culture models to accelerate drug discovery CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s...

CN Bio’s PhysioMimix™ technology receives FDA recognition

by CN Bio. | Jan 11, 2021 | Press releases

FDA publication demonstrates advantages of PhysioMimix™ in drug safety and metabolism applications, over standard techniques Represents the first co-published, peer-reviewed article between a microphysiological system provider and a regulator Characterizing the...

CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients

by CN Bio. | Dec 15, 2020 | Press releases

CN Bio’s Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following SARS-CoV-2 infection CN Bio, a leading cell culture company, that has developed single and multi-organ...

CN Bio to provide drug metabolism and safety toxicity testing services

by CN Bio. | Oct 27, 2020 | Press releases

Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology CN Bio, a leading 3D cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy...

CN Bio makes key senior appointments to support international commercial development

by CN Bio | Aug 5, 2020 | Press releases

Appointments include James Craven as Chief Commercial Officer and Brian Manning as US Head of Sales Cambridge, UK, 05 August 2020: CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy...

CN Bio Innovations raises $9 million USD (c. £6.9 million GBP)

by CN Bio. | Mar 2, 2020 | Press releases

Investment will support commercial development in key markets, US and Europe  Funding led by CITIC Securities Investment and supported by existing investor CN Innovations Headquarters relocated to larger premises in Cambridge Science Park, a leading UK life sciences...
« Older Entries

Recent Posts

  • CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research 1st March 2021
  • Flowing to the Beat of Your Heart 17th February 2021
  • How a novel in vitro Liver-on-a-Chip model of fatty liver disease is being used to help prevent a global healthcare crisis. 27th January 2021

Categories

  • Business
  • Media Coverage
  • NASH
  • OOC Blog
  • Press releases
  • Uncategorised
Website built and designed by Website Energizers LTD | © 2021 CN Bio Innovations | Registered No. 06517359 | VAT No. 978184563 | Privacy Policy | Terms | Sitemap
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok